Skip to main content
Pherecydes Pharma logo

Pherecydes Pharma — Investor Relations & Filings

Ticker · ALPHE ISIN · FR0011651694 LEI · 894500LYT3UUN58X3I68 PA Professional, scientific and technical activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2021-05-06 Regulatory Filings
Country FR France
Listing PA ALPHE

About Pherecydes Pharma

https://www.pherecydes-pharma.com/en/

Pherecydes Pharma is a clinical-stage biotechnology company specializing in the research and development of phage therapy to combat antibiotic-resistant bacterial infections. The company develops targeted treatments using bacteriophages, which are naturally occurring viruses that specifically infect and destroy bacteria. Its therapeutic approach focuses on providing personalized solutions for severe infections, particularly those caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company utilizes a proprietary phage bank and a diagnostic tool to determine the most effective phages for each patient's specific bacterial strain. In 2023, Pherecydes Pharma merged with Erytech to form Phaxiam Therapeutics, combining expertise to advance phage therapy as a mainstream anti-infective solution.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated May 6, 2021, announcing that a new scientific article highlighting the beneficial effect of Pherecydes Pharma's phages in treating a prosthetic knee infection has been published in 'Frontiers in Medicine'. This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER). It is an announcement about external scientific validation and publication related to the company's product/technology. This type of announcement, which details scientific progress, clinical findings, or regulatory milestones outside of standard financial reporting, often falls under general Regulatory Filings (RNS) or, if it were a presentation, Investor Presentation (IP). Since it is a press release announcing a publication, and there is no specific category for 'Scientific Publication Announcement', RNS serves as the most appropriate general regulatory/news filing category for non-financial, non-management-change news. Given the content is about a scientific publication and its implications, RNS is the best fit among the provided options for a general corporate news release.
2021-05-06 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated May 6, 2021, announcing the publication of a scientific article in *Frontiers in Medicine* detailing the successful compassionate use of Pherecydes Pharma's phages to treat a prosthetic knee infection. The text focuses on scientific findings, collaboration with a hospital (HCL), and future clinical trial plans. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement about scientific progress and publication, which fits best under general Regulatory Filings (RNS) as it is a public disclosure of material information that doesn't fit the more specific categories like DIV, CAP, or MANG. Since it is an announcement of a scientific paper, and not the paper itself, RNS is the most appropriate general category for this type of corporate news release.
2021-05-06 French
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Report Publication Announcement Classification · 99% confidence The document is a short press release dated April 30, 2021, titled "Mise à disposition du rapport financier annuel 2020" (Making available of the 2020 annual financial report). The core message is that the 'rapport financier annuel 2020' (2020 annual financial report) has been made available to the public and provides a link to consult it. According to Rule #2 (The "MENU VS MEAL" RULE), when a document is short and announces that a report has been published or made available, it should be classified as a Report Publication Announcement (RPA), not the report itself (which would be 10-K or IR). The document length (3279 chars) confirms it is short.
2021-04-30 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document is a press release dated April 29, 2021, announcing that Pherecydes Pharma obtained a non-dilutive loan of 2 million euros from Bpifrance under the 'State Guaranteed Loan – Innovation Support' plan. This announcement details a specific financing activity (a loan) and its terms. This directly aligns with the definition of 'Capital/Financing Update' (Code: CAP), which covers company fundraising and financing activities.
2021-04-29 French
Inside Information / Other news releases
Capital/Financing Update Classification · 99% confidence The document is a press release dated April 29, 2021, announcing that Pherecydes Pharma has obtained a €2 million non-dilutive loan (financing) from Bpifrance. This announcement directly concerns the company's fundraising and capital structure activities. Based on the provided definitions, this aligns perfectly with the 'Capital/Financing Update' category. Filing Type Code: CAP (Capital/Financing Update).
2021-04-29 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated April 28, 2021, announcing that the investment bank Portzamparc has initiated research coverage on Pherecydes Pharma, assigning a 'Buy' recommendation and a target price. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about external research coverage, which often falls under general investor relations communication. Since it is an announcement related to investor information (research initiation) but doesn't fit perfectly into the specific categories like 'IP' (Investor Presentation) or 'ER', and it is a formal press release, the most appropriate general category for non-standard regulatory/investor announcements is 'RNS' (Regulatory Filings/General Announcements), or potentially 'IR' if interpreted broadly as investor news, but 'RNS' serves as the best fallback for specific announcements not covered elsewhere. Given the context of an analyst initiation report being announced, it is a form of investor communication. However, since it is a press release announcing third-party research, and not a core financial report, 'RNS' is the most suitable general classification for this type of market communication that doesn't fit the specific report types.
2021-04-28 French

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.